Related Experiment Videos
Safety experience from long-term treatment with omeprazole
S Joelson1, I B Joelson, P Lundborg
1Research Laboratory, Astra Hässle AB, Mölndal, Sweden.
Digestion
|January 1, 1992
Summary
Long-term omeprazole use for peptic ulcers and reflux oesophagitis showed a safety profile similar to short-term use and H2-receptor antagonists. Adverse events decreased over time, with no new safety concerns identified in this extensive study.
Area of Science:
- Gastroenterology
- Pharmacology
- Clinical Therapeutics
Background:
- Peptic ulcer disease and reflux oesophagitis are common gastrointestinal conditions requiring long-term management.
- Proton pump inhibitors like omeprazole are frequently prescribed, necessitating evaluation of their long-term safety.
- Comparison with established treatments, such as H2-receptor antagonists, is crucial for understanding omeprazole's safety profile.
Purpose of the Study:
- To assess the safety and tolerability of long-term omeprazole administration (up to 6 years) in patients with poorly responsive peptic ulcer or reflux oesophagitis.
- To compare the adverse event profile of long-term omeprazole treatment with short-term omeprazole and H2-receptor antagonist therapies.
Main Methods:
- A cohort of 859 patients received omeprazole for up to 6 years for prevention of relapse.
- Adverse events were systematically recorded and compared with data from short-term treatment groups: omeprazole (n=2,818), ranitidine (n=1,572), and cimetidine (n=891).
Main Results:
- The adverse event pattern during long-term omeprazole treatment was comparable to short-term omeprazole and H2-receptor antagonist use.
- No new adverse events emerged with prolonged omeprazole therapy, and the incidence of reported events decreased over time.
- No serious adverse events were deemed causally related to omeprazole.
Conclusions:
- Omeprazole demonstrates excellent tolerability in both short-term and long-term treatment regimens.
- Long-term omeprazole therapy for peptic ulcer and reflux oesophagitis is safe and does not present unique adverse event profiles compared to shorter durations or alternative treatments.